Patent Number: 7,820,717

Title: CCR9 inhibitors and methods of use thereof

Abstract: The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compounds represented by Structural Formula I in research, therapeutic, prophylactic and diagnostic methods.

Inventors: Fleming; Paul (Wellesley, MA), Harriman; Geraldine C. B. (Charlestown, RI), Shi; Zhan (Concord, MA), Chen; Shaowu (Sudbury, MA)

Assignee: Millennium Pharmaceuticals, Inc.

International Classification: C07C 311/15 (20060101); A61P 29/00 (20060101); A61K 31/50 (20060101); C07D 213/02 (20060101); C07D 237/06 (20060101); C07D 239/69 (20060101); A61K 31/18 (20060101); A61K 31/44 (20060101); A61P 1/00 (20060101)

Expiration Date: 2018-10-26 0:00:00